By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in a late-stage study, when tested in patients with active thyroid eye disease.

A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active ...

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to ...

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that ...